Falsified Medicines: MHRA publishes Class 4 FMD Medicines Information
Recommendation
Wednesday, 30 April 2025 9 .00 - 17.30 h
How to Audit Logistics Service Providers
Register now for ECA's GMP Newsletter
The Medicines and Healthcare products Regulatory Agency (MHRA) is currently investigating an incident where several medicines appear to have left the legal supply chain and have then been re-introduced via WDA(H) 50340 HMS Wholesale Limited. This license has since then been terminated.
In a Falsified Medicines Directive (FMD) Alert published 19 March 2020, the MHRA says that "the products do appear to be genuine with legitimate batch numbers. These products are thought to have been stolen from the legitimate supply chain in early 2019 and reintroduced into the supply chain between May and August 2019. This means that the correct transport and storage conditions cannot be guaranteed and while unlikely, could impact their effectiveness."
Only the batch numbers mentioned in appendix 1 of the PDF are within the scope of this alert. You can download the document here.
Related GMP News
11.03.2025USP Publishes Summary of Comments on Chapter <1079.2> Regarding Mean Kinetic Temperature (MKT)
11.03.2025EMA: No further Extension of GDP Certificates in 2025
11.03.2025Aide-Mémoires and Checklists in GDP Audits - Benefits and Risks
13.02.2025MHRA updates Guidance on Sourcing Medicines for the UK Market
13.02.2025First GDP Non-Compliance Report of 2025: Data Integrity Issues at Hungarian Wholesaler